Zai Lab Limited (ZLAB) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - September 10, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Zai Lab Limited ("Zai Lab Limited") (NASDAQ: ZLAB) concerning possible violations of federal securities laws.

Zai Lab issued a press release on September 3, 2025, announcing that "the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed." While the interim analysis of the trial revealed a significant improvement in overall survival when compared to chemotherapy alone, the final analysis showed that the previously noted survival advantage had diminished. Zai Lab stated that "[b]ased on the updated results of the FORTITUDE-101 trial, Zai Lab intends to await the results of FORTITUDE-102, evaluating bemarituzumab in combination with nivolumab and chemotherapy in the same patient population, prior to regulatory filing. Data readout from FORTITUDE-102 is anticipated by the end of 2025 or the first half of 2026."

Following this news, Zai Lab's American Depositary Receipt ("ADR") price fell over 6% on September 3, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/zai-lab-limited-lawsuit-submission-form?prid=166496&wire=5&utm_campaign=59

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265931